Dr. David M. Goldenberg is President of the Garden State Cancer Center and the Center for Molecular Medicine and Immunology, a specialized cancer research center located in Belleville, New Jersey.  He has also been Adjunct Professor of Microbiology and Immunology at New York Medical College, Valhalla, New York, and Adjunct Professor of Medicine and Surgery at New Jersey Medical School, UMDNJ, and is one of the recognized pioneers in the field of cancer imaging and therapy with monoclonal antibodies, which he coined as radioimmunodetection and radioimmunotherapy.

Born in Brooklyn, New York, Dr. Goldenberg received his S.B. degree from the University of Chicago, Division of Biological Sciences in December 1958.  He received his M.D. degree, Magna Cum Laude, from the University of Heidelberg School of Medicine in Germany in 1966, and his Sc.D. degree, Cum Laude, from the University of Erlangen-Nuremberg Faculty of Natural Sciences, Germany in 1965.

In 1968, Dr. Goldenberg returned to the USA to the position of Associate Research Professor of Pathology, University of Pittsburgh School of Medicine, and Staff Pathologist at the VA Hospital, in Pittsburgh, Pennsylvania (1970-72).

In 1972, he moved to Kentucky where he was appointed Professor of Pathology and Director of Experimental Pathology at the University of Kentucky.  In Kentucky, he was also the founder and first President of the Ephraim McDowell Cancer Research Center.  In 1979, he took a sabbatical leave at the Immunology Branch Division of Cancer Biology and Diagnosis, National Cancer Institute, NIH in Bethesda, Maryland.  Dr. Goldenberg moved to New Jersey in 1983 to become President of the Center for Molecular Medicine and Immunology/Garden State Cancer Center, his current post, and he now resides in Mendham, New Jersey.  In 1982, he also founded the biotechnology firm, Immunomedics, Inc., and has been Chairman of the Board of this public company since 1983. He is also the founder and Chairman of IBC Pharmaceuticals, Inc., a subsidiary of Immunomedics, which is developing bispecific antibody-pretargeting technologies for cancer therapy.

During his career, Dr. Goldenberg has written or co-authored approximately 1,500 journal articles, abstracts and book chapters on cancer immunology and other topics of cancer research. He has served on the editorial boards for numerous journals, including Journal of Cancer Research and Clinical Oncology, Cancer, Cancer Research, Tumor Targeting, Tumor Biology, and Journal of Nuclear Medicine.  Dr Goldenberg is active in a number of scientific and medical societies, including the American Association for Cancer Research, Society of Nuclear Medicine, European Association of Nuclear Medicine, German Society for Nuclear Medicine, American Association of Immunologists, International Society for Oncodevelopmental Biology and Medicine, Society for Experimental Biology and Medicine, Society for Biological Therapy, American Society of Hematology, European Association of Hematology, and American Society of Clinical Oncology.

In recognition of his research contributions, Dr. Goldenberg was given the University of Kentucky Research Foundation Award in 1978, a Silver Medallion and Certificate from the German Fund for Cancer Research in Bonn in 1979, an “Outstanding Investigator Award” grant from the National Cancer Institute in 1985 and 1992, and the New Jersey Pride Award in Science and Technology in 1986.  He was also cited by a Resolution of Commendation of the New Jersey General Assembly and the New Jersey Senate in 1985/86.  Dr. Goldenberg was honored as the ninth Otto Herz Lecturer of Tel Aviv University Faculty of Life Sciences.  In addition, he received the 1991 3M Mayneord Memorial Award and Lectureship of the British Institute of Radiology for his contributions to the development of radiolabeled antibodies used in the imaging and treatment of cancer.  Dr. Goldenberg was the co-recipient of the 1994 Abbott Award, sponsored by the International Society of Oncodevelopmental Biology and Medicine, the recipient of the 1994 Sarabhai Memorial Oration Award, sponsored by the Society of Nuclear Medicine, India, and the 2002 Erin Berven Prize recipient and Lecturer of the Swedish Oncology Society, including a medal from the Swedish Medical Society.  In 2003, he received the Garden State Cancer Center Award for Special Scientific Achievements, and in 2004 he received the Distinguished Scientist Award of the Clinical Ligand Assay Society. In 2005, Dr. Goldenberg received the Paul C. Aebersold Award, the highest recognition given by the Society of Nuclear Medicine for contributions to the basic sciences with applications to the practice of nuclear medicine. Also in 2005, he was named Inventor of the Year by The Research and Development Council of New Jersey for being the recipient of over 180 U.S. and foreign patents, particularly in the area of applying monoclonal antibodies to the detection and treatment of various diseases.